National surveys of primary care physicians demonstrate that placebo use is prevalent. Against their widespread use, until recently, it was assumed among researchers that placebos must be deceptively prescribed for beneficial effects to be elicited. However, a new programme of research in placebo studies indicates that it may be possible to harness placebo effects in clinical practice via ethical, non-deceptively prescribed 'open label placebos' ('OLPs'). To date, there have been 14 small scale clinical and experimental trials into OLPs. Results suggest therapeutic potential of these treatments for a range of conditions and symptoms. In this evidence-based Analysis we identify conceptual issues that, if not given due consideration, risk undermining research methodologies in OLP trials. Counterintuitively, owing to the nuances posed by placebo terminology, and the difficulties of designing placebos controls in OLP trials, we suggest that experimentalists reflect more deeply when formulating adequate comparison groups. Further research is needed to disentangle which specific components of OLPs are effective, such as: the rationale provided to participants; the quality of provider interaction; and/or the action of taking the pills. We conclude with recommendations for how researchers might take up the significant challenge of devising optimal placebo controls for OLP clinical trials. Although these issues are intricate, they are not merely academic: without due diligence to conceptual, and as a consequence, methodological considerations, OLP effect sizes may be over- or underestimated. We conclude that there may yet be potential to use OLPs in medical practice but clinical translation depends on rigorously controlled research.
Keywords: clinical trials; general medicine; medical ethics; primary care.
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Deceptive but Not Open Label Placebos Attenuate Motion-Induced NauseaK Barnes et al. J Psychosom Res 125, 109808. PMID 31426018.No positive evidence for OLP effects in nausea were observed. However, a deceptive effect in VR was observed. These findings raise questions regarding the efficacy of ope …
Are open-Label Placebos Ethical? Informed Consent and Ethical EquivocationsC Blease et al. Bioethics 30 (6), 407-14. PMID 26840547.The doctor-patient relationship is built on an implicit covenant of trust, yet it was not until the post-World War Two era that respect for patient autonomy emerged as an …
Deceptive and Nondeceptive Placebos to Reduce Pain: An Experimental Study in Healthy IndividualsT Kube et al. Clin J Pain 36 (2), 68-79. PMID 31899746.Increase in pain tolerance was larger in the 3 treatment groups compared with NT, whereas the treatment groups did not differ from each other. Further results showed that …
Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet]EL LeBlanc et al. PMID 30354042. - ReviewWe found that behavior-based weight-loss interventions with or without weight loss medications resulted in more weight loss than usual care conditions. The degree of weig …
Placebos Without Deception: Outcomes, Mechanisms, and EthicsL Colloca et al. Int Rev Neurobiol 138, 219-240. PMID 29681327. - ReviewScientific research indicates that open-label and dose-extending placebos (that patients know are placebos) can elicit behavioral, biological, and clinical outcome change …
Cited by 2 PubMed Central articles
Placebos Are Part of the Solution, Not the Problem. An Exemplification of the Case of Antidepressants in Pediatric Chronic Pain ConditionsC Locher et al. Front Psychiatry 10, 998. PMID 32038331.
Are Conditioned Open Placebos Feasible as an Adjunctive Treatment to Opioids? Results From a Single-Group Dose-Extender Pilot Study With Acute Pain PatientsMH Bernstein et al. Psychother Psychosom 88 (6), 380-382. PMID 31563914.